CONMED appoints Mark Kaye as director; declares $0.20 quarterly dividend

CONMED Corp

Board expanded to nine; Mark Kaye appointed effective Feb 24, 2025, with Audit and Strategy committee assignments.
Quarterly dividend of $0.20 per share declared, payable April 4, 2025 to holders of record March 14, 2025.
Kaye currently EVP & CFO of Elevance Health; previously CFO of Moody's and senior finance roles at MassMutual and ING.
Kaye received prorated equity grant of 152 RSUs and options on 1,846 shares, vesting in full on Feb 24, 2026.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark Kaye

Director

CNMD · CONMED Corp

Effective: 2025-02-24
Filed: February 25, 2025, 6:59 PM ET

On February 24, 2025, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Mark Kaye as a director effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Kaye was appointed as Director at CONMED Corp.

Action: appointed
Role: Director

Exact text from the filing

On February 24, 2025, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Mark Kaye as a director effective immediately.

View on SEC.gov

CONMED Corp filing history →

Source: SEC EDGAR

accession 0001174947-25-000234

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.